InDex Pharmaceuticals, a pharmaceutical company, completed the merger with Flerie Invest, an active and global long-term life science investor, in a SEK3bn deal. "I am very pleased that the evaluation has resulted in the proposed Transaction, as Flerie came out as the best option. Flerie has a highly regarded Board and management with excellent track record​ and a balanced risk profile. The attractive deal terms include a possibility for share redemption, in addition to being able to trade which ensures that we can offer shareholders optionality," Jenny Sundqvist, InDex Pharmaceuticals CEO.